CD274 and neoplasm: Blocking immune checkpoint pathways such as PD-1/programmed death-ligand 1 (PD-L1) and CTLA-4 not only enhances T cell-mediated tumor suppression but also promotes inflammatory responses in vascular lesions, potentially leading to plaque rupture and thrombotic events such as acute coronary syndrome and cerebral infarction [13].